532 terminated. 532 Phase 1, 189 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 532 | Terminated 532 |
| Phase 2 | 189 | Terminated 189 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas BI 765049 - Colorectal Carcinoma, Gastric Carcinoma | Phase 1 | Terminated | Boehringer Ingelheim | 14 | 2025-03-28 | 2026-10-27 |
| A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. PF-07985045, Gemcitabine, Nab-paclitaxel - Carcinoma, Pancreatic Ductal, Colorectal Neoplasms | Phase 1 | Terminated | Pfizer | 30 | 2024-12-10 | 2026-05-22 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation AZD0022, Cetuximab - Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Terminated | AstraZeneca | 17 | 2024-10-18 | 2026-03-18 |
| First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers ATX-559 - Advanced Solid Tumors, Breast Cancer Recurrent | Phase 1 | Terminated | Accent Therapeutics | 17 | 2024-10-11 | 2026-02-24 |
| A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Livmoniplimab, Budigalimab - Hepatocellular Carcinoma (HCC) | Phase 1 | Terminated | AbbVie | 3 | 2024-09-11 | 2026-10-21 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study of SGN-MesoC2 in Advanced Solid Tumors PF-08052666 - Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 19 | 2024-08-02 | 2026-07-07 |
| A Study of PHN-010 in Patients With Advanced Solid Tumors PHN-010 - Lung Cancer, Colon Cancer | Phase 1 | Terminated | Pheon Therapeutics | 26 | 2024-07-01 | 2026-01-29 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers BGB-3245, Panitumumab - Colorectal Cancer, Pancreatic Ductal Cancer | Phase 1 | Terminated | MapKure, LLC | 13 | 2024-04-18 | 2025-04-20 |
| A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors ASP4396 - Solid Tumor | Phase 1 | Terminated | Astellas Pharma Inc | 60 | 2024-04-16 | 2026-10-23 |
| Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma BNT321 0.5 mg/kg, BNT321 DL 2, mFOLFIRINOX - Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 1 | 2024-03-27 | 2025-10-31 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 BI 765049, Ezabenlimab - Gastrointestinal Cancer, Lung Cancer | Phase 1 | Terminated | Boehringer Ingelheim | 21 | 2024-02-16 | 2026-10-14 |
Showing 20 of 532. Sign in to see all of them.
Colorectal Neoplasms (188) · Pancreatic Neoplasms (153) · Carcinoma, Non-Small-Cell Lung (106) · Stomach Neoplasms (87) · Carcinoma, Hepatocellular (79) · Colonic Neoplasms (64) · Melanoma (63) · Breast Neoplasms (60) · Neoplasms (60) · Ovarian Neoplasms (60) · Neoplasm Metastasis (58) · Squamous Cell Carcinoma of Head and Neck (51) · Rectal Neoplasms (49) · Esophageal Neoplasms (46) · Carcinoma, Renal Cell (44)
Digestive System Diseases (529) · Neoplasms by Site (526) · Neoplasms (472) · Gastrointestinal Diseases (335) · Gastrointestinal Neoplasms (322) · Intestinal Diseases (253) · Intestinal Neoplasms (252) · Neoplasms by Histologic Type (234) · Colonic Diseases (228) · Rectal Diseases (225) · Neoplasms, Glandular and Epithelial (204) · Endocrine Gland Neoplasms (201) · Endocrine System Diseases (201) · Carcinoma (178)
Gemcitabine (61) · pembrolizumab (40) · Capecitabine (32) · Fluorouracil (30) · Oxaliplatin (30) · 130-nm albumin-bound paclitaxel (27) · Bevacizumab (23) · Cetuximab (23) · Nivolumab (22) · Irinotecan (20) · Leucovorin (20) · Radiotherapy (19) · Cyclophosphamide (18) · Albumin-Bound Paclitaxel (16) · Cisplatin (15)
National Cancer Institute (NCI) (26) · Pfizer (20) · Washington University School of Medicine (13) · Incyte Corporation (11) · Novartis Pharmaceuticals (10) · M.D. Anderson Cancer Center (8) · Merck Sharp & Dohme LLC (8) · AbbVie (6) · Seagen Inc. (6) · Boehringer Ingelheim (5) · Bristol-Myers Squibb (5) · Eli Lilly and Company (5) · Hoffmann-La Roche (5) · ImmunityBio, Inc. (5) · Massachusetts General Hospital (5)
United States (417) · Spain (50) · Australia (40) · France (40) · United Kingdom (36) · South Korea (34) · Canada (30) · Taiwan (28) · Germany (27) · China (25) · Belgium (24) · Japan (23) · Italy (20) · Singapore (17) · Netherlands (15)
David S Schrump, M.D. (5) · Andrew Ko, MD (3) · Howard Safran, MD (3)
PMID 31527168, PMID 35046060, PMID 39863139, PMID 18197583, PMID 18845990, PMID 19525947, PMID 19738454, PMID 20305636, PMID 20930628, PMID 21516509, PMID 23553066, PMID 24231241, PMID 24285980, PMID 25290091, PMID 25627002, PMID 25679067, PMID 27256874, PMID 27681866, PMID 27784746, PMID 28677263, PMID 28939558, PMID 29119276, PMID 29158367, PMID 29322091, PMID 29735994, PMID 29808006, PMID 29934438, PMID 30139840, PMID 30634942, PMID 30796035, PMID 30858085, PMID 30911664, PMID 31401903, PMID 31802410, PMID 32238921, PMID 32361265, PMID 32379297, PMID 32410080, PMID 32524319, PMID 32598257, PMID 32788205, PMID 32819975, PMID 32891715, PMID 33016924, PMID 33039812, PMID 33355229, PMID 33677480, PMID 33686452, PMID 33738668, PMID 34187739
2019 (9), 2023 (9), 2018 (8), 2017 (6), 2014 (5), 2015 (5), 2016 (3), P30CA043703 (3), P50CA196510 (3), 2009 (2), P30CA068485 (2), U01CA121947 (2), 2025 (1), N01CM00071 (1), N01CM00100 (1)